A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
85 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
Recruiting - Novartis Investigative Site
CABA, Argentina
Recruiting - Novartis Investigative Site
Río Cuarto, Argentina
Recruiting - Novartis Investigative Site
San Miguel de Tucumán, Argentina
Recruiting - Novartis Investigative Site
Santa Fe, Argentina
Recruiting
- Novartis Investigative Site
Camperdown, New South Wales, Australia
Recruiting - Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Recruiting - Novartis Investigative Site
New Lambton Heights, New South Wales, Australia
Recruiting - Novartis Investigative Site
Adelaide, South Australia, Australia
Recruiting
- Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Recruiting
- Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
- Novartis Investigative Site
Prague, Czechia
Recruiting - Novartis Investigative Site
Prague, Czechia
Recruiting
- Novartis Investigative Site
Angers, France, France
Recruiting - Novartis Investigative Site
Brest, France
Recruiting - Novartis Investigative Site
Clamart, France
Recruiting - Novartis Investigative Site
Grenoble, France
Recruiting - Novartis Investigative Site
Montpellier, France
Recruiting - Novartis Investigative Site
Nice, France
Recruiting - Novartis Investigative Site
Pessac, France
Recruiting - Novartis Investigative Site
Poitiers, France
Recruiting - Novartis Investigative Site
Saint-Priest-en-Jarez, France
Recruiting - Novartis Investigative Site
Strasbourg, France
Recruiting - Novartis Investigative Site
Toulouse, France
Recruiting - Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Recruiting
- Novartis Investigative Site
Regensburg, Bavaria, Germany
Recruiting - Novartis Investigative Site
Dresden, Saxony, Germany
Recruiting - Novartis Investigative Site
Berlin, Germany
Recruiting - Novartis Investigative Site
Berlin, Germany
Recruiting - Novartis Investigative Site
Giessen, Germany
Recruiting - Novartis Investigative Site
Greifswald, Germany
Recruiting - Novartis Investigative Site
Heidelberg, Germany
Recruiting - Novartis Investigative Site
Homburg, Germany
Recruiting
- Novartis Investigative Site
Athens, Greece
Recruiting - Novartis Investigative Site
Chaïdári, Greece
Recruiting - Novartis Investigative Site
Thessaloniki, Greece
Recruiting
- Novartis Investigative Site
Foggia, FG, Italy
Recruiting - Novartis Investigative Site
Monza, MB, Italy
Recruiting - Novartis Investigative Site
Palermo, PA, Italy
Recruiting - Novartis Investigative Site
Pavia, PV, Italy
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Oct 2024
- Primary completion
- 29 Nov 2028
- Completion
- 31 Dec 2028
- Last update posted
- 29 Apr 2026
- Registered enrollment
- 232
- Registry id
- NCT06649110
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.